Investing.com — Bank of America analysts see the potential for medtech stocks to continue gaining momentum as they appear less vulnerable to potential healthcare-related controversies tied to RFK Jr. headlines. The bank notes that recent developments have bolstered the sector, with medtech rebounding from historically low valuations to trade more closely in line with its 10-year average discount to the Tools sector. In just two days, medtech’s discount to Tools narrowed